Who are GC5107's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Semaglutide Pen Injector, Semaglutide (Rybelsus®), Exenatide twice daily (BID), Liraglutide+standard-of-care treatment, exenatide (Byetta), Semaglutide Treatment.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gc5107.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

GC5107 — Competitive Intelligence Brief

GC5107 (GC5107) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: GLP-1 receptor agonist. Area: Endocrinology.

phase 3 GLP-1 receptor agonist GLP-1R Endocrinology Biologic Live · refreshed every 30 min

Target snapshot

GC5107 (GC5107) — GC Biopharma Corp. GC5107 is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that enhances insulin secretion and reduces glucagon release to lower blood glucose levels.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
GC5107 TARGET	GC5107	GC Biopharma Corp	phase 3	GLP-1 receptor agonist	GLP-1R
Semaglutide Pen Injector	Semaglutide Pen Injector	University of Pennsylvania	marketed	GLP-1 receptor agonist	GLP-1R
Semaglutide (Rybelsus®)	Semaglutide (Rybelsus®)	Instituto Mexicano del Seguro Social	marketed	GLP-1 receptor agonist	GLP-1R (GLP-1 receptor)
Exenatide twice daily (BID)	Exenatide twice daily (BID)	Eli Lilly and Company	marketed	GLP-1 receptor agonist	GLP-1R
Liraglutide+standard-of-care treatment	Liraglutide+standard-of-care treatment	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	GLP-1 receptor agonist	GLP-1R
exenatide (Byetta)	exenatide (Byetta)	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	marketed	GLP-1 receptor agonist	GLP-1R
Semaglutide Treatment	Semaglutide Treatment	University Health Network, Toronto	marketed	GLP-1 receptor agonist	GLP-1R

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (GLP-1 receptor agonist class)

Hanmi Pharmaceutical Company Limited · 30 drugs in this class
Eli Lilly and Company · 8 drugs in this class
Novo Nordisk A/S · 6 drugs in this class
GlaxoSmithKline · 6 drugs in this class
Sanofi · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
Hangzhou Sciwind Biosciences Co., Ltd. · 3 drugs in this class
Jiangsu Hansoh Pharmaceutical Co., Ltd. · 2 drugs in this class
Huons Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GC5107 — Competitive Intelligence Brief. https://druglandscape.com/ci/gc5107. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab